SK bioscience Advances Development of Next-Generation Infectious Disease Prevention

The Phase 1b study will enroll approximately 80 infants aged 2 weeks to 8 months and evaluate the safety and pharmacokinetic profile of RSM01. Through the study, SK bioscience aims to assess the clinical development potential of RSM01 as an RSV preventive antibody for.

Gates MRI conducted the candidate's early-stage research and Phase 1a clinical development in adults. The new Phase 1b study marks an important step in expanding RSM01's clinical development from adults to infants, a key population targeted for RSV prevention.

What Happened

RSV is a major respiratory virus that can cause severe lower respiratory tract infections in infants and young children, with a particularly significant disease burden during the first months of life. Because very young infants may have limitations in developing sufficient active.

• RSM01 is a preventive antibody candidate that SK bioscience secured through a licensing agreement with Gates MRI in February 2026.

• According to global market research firm Evaluate Pharma, the worldwide market for RSV preventive antibodies is projected to reach USD 4.5 billion by 2032.

• With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and.

Key Details

Against this backdrop, the development of antibody-based approaches to RSV prevention continues to advance globally. With several preventive antibodies already commercialized, primarily in developed markets, demand for RSV prevention among infants and young children is expected to continue driving market growth.

• Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe.

• SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world.

• Building on these global partnerships, the company plans to further broaden its infectious disease prevention portfolio.

Why It Matters

SK bioscience is expanding its respiratory disease prevention portfolio from cell-culture influenza vaccines and pneumococcal vaccines into RSV antibody-based preventive technologies. By building R&D capabilities spanning both vaccines and antibody-based approaches, the company aims to address a broader range of unmet needs.

• Centers for Disease Control and Prevention (CDC).

• SK bioscience continues to expand its global R&D network through collaborations including the joint development of a pneumococcal vaccine with Sanofi, its RSV prevention partnership with Gates MRI, and the introduction of injectable rotavirus.

What Reports Say

Coverage of the story so far points to:

• Continued reporting by BioSpace as more details emerge